Illumina Stock Today
| ILMN Stock | USD 95.76 1.80 1.92% |
PerformanceVery Weak
| Odds Of DistressLow
|
Illumina is selling at 95.76 as of the 25th of February 2025; that is 1.92 percent increase since the beginning of the trading day. The stock's open price was 93.96. Illumina has less than a 14 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Note, on October 2, 2024, Representative Michael C Burgess of US Congress acquired $15k to $50k worth of Illumina's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of July 2000 | Category Healthcare | Classification Health Care |
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The company was incorporated in 1998 and is based in San Diego, California. Illumina operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 158.4 M outstanding shares of which 6.51 M shares are currently shorted by private and institutional investors with about 3.99 trading days to cover. More on Illumina
Moving against Illumina Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Illumina Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Jacob Thaysen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Measuring and Control Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Nasdaq CTA Artificial, Nasdaq 100 Total, ARCA Biotechnology, SP Midcap 400, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Measuring and Control Equipment, Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal TestingCatholic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIllumina can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Illumina's financial leverage. It provides some insight into what part of Illumina's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Illumina (ILMN) is traded on NASDAQ Exchange in USA. It is located in 5200 Illumina Way, San Diego, CA, United States, 92122 and employs 8,970 people. Illumina is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 14.88 B. Illumina conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 158.4 M outstanding shares of which 6.51 M shares are currently shorted by private and institutional investors with about 3.99 trading days to cover.
Illumina currently holds about 2.01 B in cash with 837 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.62.
Check Illumina Probability Of Bankruptcy
Ownership AllocationThe majority of Illumina outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Illumina to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Illumina. Please pay attention to any change in the institutional holdings of Illumina as this could imply that something significant has changed or is about to change at the company. On October 2, 2024, Representative Michael C Burgess of US Congress acquired $15k to $50k worth of Illumina's common stock.
Check Illumina Ownership Details
Illumina Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Hhg Plc | 2024-12-31 | 2.2 M | |
| Nuveen Asset Management, Llc | 2024-09-30 | 2.1 M | |
| Brown Advisory Holdings Inc | 2024-12-31 | 1.9 M | |
| Norges Bank | 2024-12-31 | 1.7 M | |
| Corvex Management Lp | 2024-12-31 | 1.7 M | |
| Alliancebernstein L.p. | 2024-12-31 | 1.7 M | |
| Northern Trust Corp | 2024-12-31 | 1.7 M | |
| Bank Of America Corp | 2024-12-31 | 1.6 M | |
| Pointstate Capital Lp | 2024-12-31 | 1.6 M | |
| Blackrock Inc | 2024-12-31 | 19.3 M | |
| Capital World Investors | 2024-12-31 | 18 M |
Illumina Historical Income Statement
Illumina Stock Against Markets
Illumina Corporate Management
| Steven Hoffman | Segment Sequencing | Profile | |
| Pat Leckman | Interim Officer | Profile | |
| Ankur Dhingra | Chief Officer | Profile | |
| Nicole Berry | Head RegionAmericas | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Illumina. If investors know Illumina will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Illumina listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share (7.69) | Revenue Per Share | Quarterly Revenue Growth (0.02) | Return On Assets |
The market value of Illumina is measured differently than its book value, which is the value of Illumina that is recorded on the company's balance sheet. Investors also form their own opinion of Illumina's value that differs from its market value or its book value, called intrinsic value, which is Illumina's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Illumina's market value can be influenced by many factors that don't directly affect Illumina's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Illumina's value and its price as these two are different measures arrived at by different means. Investors typically determine if Illumina is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Illumina's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.